October 28, 2020 /

Catabasis Phase 3 PolarisDMD Trial Results (October 27, 2020)

Posted on October 28, 2020

On October 26, 2020 Catabasis announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy did not meet its primary or secondary endpoints. Catabasis joined PPMD for a webinar on October 27, 2020 to discuss the trial and results in more detail, as well as the company’s plans for the edasalonexent program going forward.

Join Our Mailing List